Navigation Links
Sensitizing prostate cancer to radiotherapy
Date:5/9/2011

Men with prostate cancer whose disease has spread locally from inside the prostate to immediately outside it are primarily treated with radiation therapy. However, disease recurs in approximately half of these individuals. Strategies to enhance the efficacy of this treatment and thereby decrease the incidence of disease recurrence are clearly needed. Shawn Lupold and colleagues, at Johns Hopkins University School of Medicine, Baltimore, have now developed an approach that enhances the therapeutic effects of radiation therapy in mice bearing human prostate cancer xenografts. Specifically, they selectively sensitized the prostate cancer cells to radiation therapy by knocking down expression of the gene responsible for making the protein DNAPK, which is important for repairing damaged DNA. Lupold and colleagues hope that this approach can be developed for the treatment of locally advanced prostate cancer.


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
734-546-5242
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Surgery reduces risk of mortality due to prostate cancer even for low-risk groups
2. Aggressive Treatment May Be Beneficial for Early Prostate Cancer
3. Researchers find that aspirin reduces the risk of cancer recurrence in prostate cancer patients
4. Tissue spacers reduce risk of rectal injury for prostate cancer patients
5. MRI locates prostate cancer recurrence at extremely low PSA levels
6. Scripps Research wins more than $2 million to study prostate cancer
7. Heart-Healthy Omega-3s Not Healthy for Prostate: Study
8. Acupuncture May Help Ease Hot Flashes Tied to Prostate Cancer Treatment
9. Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
10. Acupuncture relieves hot flashes from prostate cancer treatment
11. Study suggests another look at testosterone-prostate cancer link
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... The ... care facility – Avamere Transitional Care of Puget Sound ; located at ... health care center will provide patients recovering from illness or injury with intensive ...
(Date:12/5/2016)... VA (PRWEB) , ... December 05, 2016 , ... ... today announced it has been featured in SuperbCrew magazine, a leading online tech ... tech world. This interview, now featured on SuperbCrew.com, explores the state of enterprise ...
(Date:12/5/2016)... ... ... Researchers at Johns Hopkins All Children’s Hospital want to learn more about ... of three years, researchers will study concussions and changes in brain function by monitoring ... sensors, will track the location and force of the hit. The sensors store data ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy ... through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the ... 26 people will be diagnosed with epilepsy within their lifetime. With such a ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Sanovas, Inc., a life science asset holding ... its wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed ... - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed ...
(Date:12/5/2016)... 2016  CVS Health, the nation,s largest pharmacy innovation ... score of 100 percent on the Corporate Equality Index ... an annual national benchmarking survey and report on corporate ... the Human Rights Campaign Foundation. "Our ... colleagues, customers and suppliers bring to CVS Health," said ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 /PRNewswire/ ... announced preliminary safety and efficacy data from a ... selective MDM2 inhibitor, suggesting that DS-3032 may be ... acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome ... of the phase 1 study of DS-3032 were presented ...
Breaking Medicine Technology: